GoldenGolden
Advanced Search
GlycoMira

GlycoMira

GlycoMira is a Salt Lake City-based therapeutics company developing synthetic glycosaminoglycan-based therapeutics for mucosal diseases.

GlycoMira is a company that develops synthetic glycosaminoglycan-based therapeutics that modulate the innate immune molecules. Its technology has the potential to address significant unmet needs for radiation oncology and chronic respiratory indications.

GlycoMira has demonstrated safety and efficacy of its lead drug candidate against a broad spectrum of inflammatory diseases with private investments, Utah state, and federal government grant awards from the National Institutes of Health. The company's current drug development is focused on Oncology and Respiratory disease indications.

GlycoMira is developing a new class of glycosaminoglycan-based therapeutics that modulate the innate immune response and have the potential to address various unmet medical needs especially in cancer and respiratory diseases.GlycoMira's proprietary synthetic glycosaminoglycans and its lead candidate drug GM-1111 reduce mucosal inflammations caused by various inducers, such as radiation, allergen, or microbial exposure.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.